379 studies found for:    "HIV Seronegativity" [CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
2 Completed HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru
Conditions: HIV Infections;   Herpes Genitalis;   HIV Seronegativity;   Syphilis
Intervention:
3 Completed HIV Prevention Preparedness Study
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
4 Completed A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: gp160 MN/LAI-2;   Biological: ALVAC-HIV MN120TMG (vCP205)
5 Completed A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Conditions: HIV Infections;   HIV Seronegativity;   Herpes Genitalis
Interventions: Drug: Acyclovir;   Drug: Acyclovir placebo
6 Completed A Study of GENEVAX-HIV, a Possible Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: APL 400-003
7 Completed Carotid Artery Thickness in HIV Infected and Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity;   Atherosclerosis
Intervention:
8 Completed HIV Incidence and Participation Retention in Pune, India
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
9 Completed A Study to Test the Safety of Three Experimental HIV Vaccines
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: HIV p24/MF59 Vaccine;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
10 Completed A Blood Test to Look at Cells of the Immune System in Healthy Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
11 Completed A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
12 Completed Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Lipopeptides LIPO-4
13 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
14 Completed Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: APL 400-003
15 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Conditions: HIV Seronegativity;   AIDS Vaccines
Intervention: Drug: VRC-HIVDNA009-00-VP
16 Completed Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
17 Completed A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203);   Biological: Aluminum hydroxide;   Biological: MF59;   Biological: rgp120/HIV-1MN
18 Unknown  HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
19 Completed Screening Protocol for HIV Vaccine Studies
Conditions: HIV Seronegativity;   HIV Infections
Intervention:
20 Completed A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: HIV p24/MF59 Vaccine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years